Latest Breaking News On - Ellen cavaleri - Page 5 : comparemela.com
U S FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
U S FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
U S FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Kadmon to Present at Upcoming Investor Conferences
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Kadmon Holdings, Inc.: Kadmon to Present at Upcoming Investor Conferences
NEW YORK, NY / ACCESSWIRE / May 25, 2021
/ Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the following virtual investor conferences:
Jefferies Virtual Healthcare Conference
Time: 9:30 a.m. ET
Raymond James Human Health Innovation Conference
Date: Monday, June 21, 2021
Time: 12:00 p.m. ET
Live audio webcasts of the presentations may be accessed on the Investors section of the Kadmon website at www.kadmon.com. Replays of the webcasts will be available for 90 days.
About Kadmon
Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Kadmon s clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.